Self-Injection Device Market to Reach US$ 35.85 Billion by 2033 at 10.78% CAGR

The Self-injection Device Market consists of medical devices that allow patients to give themselves medications without having a nurse or a doctor present. The devices concerned with this market include auto-injectors, pen injectors, needle-free systems, and wearable injectors which are quite different but all functionally similar and are widely used for chronic diseases such as diabetes, autoimmune diseases, cancer therapies, and hormonal diseases. The rising number of chronic diseases and the older population have created a demand for such drug delivery systems which are convenient, safe, and easy to use. These systems are the ones that do not require the patients to go to the hospital, hence they lower healthcare costs while making treatment adherence and quality of life better.

The trend is given additional impetus by the biologics and biosimilars market & the latter having many products developed for subcutaneous administration & prompting pharmaceutical companies to associate new medicines with sophisticated injection technologies which ensure precision and user-friendliness. Today technologies that come with ergonomic design, built-in safety features, and dose tracking as well as digital connectivity have become standard in the industry and they also contribute to the realization of better patient outcomes and engagement. The market also receives a boost from the growing trend of patients wanting to take charge of their long-term therapy, together with the adoption of telehealth. The main obstacles in this market are the long and complicated regulations and the high cost of devices.

Check valuable insights in the Self Injection Device Market report. You can easily get a sample PDF of the report - https://www.businessmarketinsights.com/sample/BMIPUB00032632

Segments Covered

By Product

• Needle-free Injectors
• Autoinjectors
• Pen Injectors
• Wearable Injectors

By Usability

• Disposable
• Reusable

By Application

• Cancer
• Autoimmune Disorders
• Hormonal Disorders
• Pain Management
• Other Applications

Market leaders and key company profiles

• Gerresheimer AG
• Becton Dickinson, Company
• Owen Mumford Ltd.
• AptarGroup, Inc.
• Pfizer Inc.
• NuGen Medical Devices
• West Pharmaceutical Services
• SHL Medical
• YPSOMED

Self Injection Device Market Drivers and Opportunities:

Increasing Incidences Needlestick Injuries From Contaminated Needles

The needlestick injuries from contaminated needles have increasingly been a major factor in the self-injection device market since they point out very high safety risks and at the same time increase the demand for devices that can help with this kind of exposure both professionally and accidentally. Injuries from needlestick occur when a used needle mistakenly punctures the skin and can, consequently, expose the healthcare worker or patient to bloodborne viruses like hepatitis B, hepatitis C, and HIV, thus highlighting not only health but psychological risks as well that are associated with traditional injection methods. According to reports, every year millions of healthcare professionals worldwide are subjected to needlestick incidents, however, it is also stated by various studies that a significant portion of them — including nurses, phlebotomists and other clinicians — have at least one such event reported over time and a notable percentage is related to the handling or disposal of sharp instruments.

Patient Preference for Self-Administration

The option of patient preference for self-administration in the self-injection device market is becoming a major factor, supported by the general trend of moving towards more autonomy, convenience, and comfort when managing chronic diseases at home. Patients undergoing long-term treatments like diabetes, rheumatoid arthritis, and other autoimmune diseases are increasingly choosing to use devices that enable them to give themselves their medications rather than depend on painful and inconvenient frequent clinic visits showed through a major root change of the patient-centric and home treatment. There is a patient survey and report which states that when given user-friendly and least painful devices, quite a number of people would definitely opt for self-injection, many of them are particularly drawn to device design features like the hidden needles, auto-injection, and feedback which indicate safety and also reduce anxiety and thus, increase confidence in self-administration.

Self Injection Device Market News and Key Development:

The self injection device market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the self injection device market are:

• In August 2024, Astria Therapeutics selected Ypsomed's YpsoMate autoinjector platform for its lead product, ATR-101, designed to treat patients with severe allergic reactions. This collaboration aims to leverage Ypsomed’s expertise in device development to enhance the delivery and administration of ATR-101, ensuring a reliable and user-friendly patient experience. By integrating Ypsomed's technology, Astria Therapeutics aims to enhance treatment outcomes and improve patient compliance in managing severe allergies, thereby positioning itself for success in the competitive therapeutic landscape.
• In May 2023, SHL Medical, a leading provider of advanced drug delivery solutions, announced a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory diseases. The agreement aims to develop an autoinjector for the clinical and potential commercial supply of MoonLake's Nanobody sonelokimab, utilizing SHL Medical's Molly autoinjector technology.
• In September 2021, Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd., announced the launch of its new Aidaptus auto-injector platform, following the successful completion of its development. The Aidaptus is a two-step, spring-powered, single-use auto-injector designed with versatility, accommodating 1mL and 2.25mL prefilled glass syringes within the same base device.

Get Premium Research Report of Self Injection Device Market Size and Growth Report at: https://www.businessmarketinsights.com/buy/BMIPUB00032632

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.

Contact us:

• If you have any questions about this report or would like further information, please contact us:
• Contact person: Ankit Mathur
• Email: sales@businessmarketinsights.com
• Phone: +16467917070